RP, Tanswell AK. The IGF-I/IGF-R1 pathway regulates postnatal lung growth and is a nonspecific regulator of alveologenesis in the neonatal rat.
IN HUMANS, 85% OF ALVEOLARIZATION occurs after birth, whereas in rats and mice alveolarization is a completely postnatal event (7) . In both humans and rodents, alveoli are initially formed from the ingrowth of septa, or secondary crests, from the walls of their larger precursors, saccules. The regulators of this process have not been completely defined but include the coordinated expression of a number of the known growth factors, such as vascular endothelial growth factor (VEGF) (20) , platelet-derived growth factor (PDGF)-AA (4) and -BB (6), hepatocyte growth factor (HGF) (33) , and fibroblast growth factor (FGF)-7 (34) . Roles for IGF-I, IGF-II, and the IGF receptor-1 (IGF-R1) are less clear.
Both IGF-I and IGF-II are reported to be widely distributed throughout the lung during the period of alveolarization (24, 50) , as is the IGF-R1 (15) . A review of the function of IGFs in the lung (41) , published some 20 years ago, concluded that there was considerable indirect evidence that activation of the IGF-R1 by the related peptides IGF-I, IGF-II, and insulin is involved in lung growth. Subsequent observations have not done a great deal, at least for the postnatal lung, to clarify the role of the IGF pathways in alveologenesis. Consistent with IGFs playing a critical role was the observation that mice with complete IGF-R1 null mutations die after birth from respiratory failure although, perhaps surprisingly, no obvious histopathological defects in lung structure were reported (25) . Those mice would, however, have died before the normal onset of alveolarization at day 3 of postnatal life. More recent studies, in which less-than-complete null mutations of IGF-R1 (consistent with survival) were induced, demonstrated longterm effects on lung growth (18) , but lung histology was not reported. This leaves unresolved whether there was an undergrown, but structurally normal, lung or whether alveologenesis was impaired. Mice with complete IGF-II null mutations have delayed fetal lung development (39) , consistent with a role for IGF-II signaling through the IGF-R1 in growth of the fetal lung. Whether IGF-II signaling through the IGF-R1 plays a role in postnatal alveologenesis remains an open question, although it has been suggested, at least in mice (2) , that IGF-II plays little or no role in postnatal growth. The IGF-I/IGF-R1 pathway has been studied during the compensatory alveologenesis that occurs following pneumonectomy, but with discrepant results (29, 35) . The IGF-R2 is only indirectly involved in positive growth regulation, through targeting bound IGF-II to lysosomes for degradation (5) .
Because the presence of elastin in the lung is essential for alveologenesis (51) , and because IGF-I has been reported to regulate tropoelastin synthesis (32) , as well as collagen synthesis (11) , by lung fibroblasts, it seemed very likely that IGF signaling through the IGF-R1 will be a critical component of alveologenesis. To test this hypothesis, we took an approach that we have previously used for other growth factors involved in alveologenesis (6, 33, 34, 52) and injected pups with either a soluble recombinant truncated human IGF-R1 (sIGF-R1), or antibodies against IGF-I and -II, to decoy IGFs and prevent binding to the endogenous IGF-R1.
MATERIALS AND METHODS

In vivo interventions. Animal experiments complied with Canadian
Council on Animal Care guidelines and were approved by the Animal Care Review Committee of the Hospital for Sick Children Research Institute. Pathogen-free timed-pregnant Sprague-Dawley rats (250 -275 g) were obtained from Charles River (St. Constant, Quebec). Pups were killed at various time points up to 14 days of age by inhalation of ethyl ether. In preliminary experiments, to determine an effective dose of sIGF-R1, rat pups received either intraperitoneal injections of PBS (5 l/g) or 3, 10, or 20 g/g sIGF-R1 (R&D Systems, Minneapolis, MN) in PBS on day 2 for death on day 4. In subsequent experiments using sIGF-R1, pups were either uninjected or received intraperitoneal injections of PBS (5 l/g) or 20 g/g sIGF-R1 in PBS on days 2 and 5 for death on days 6 or 7. Body and lung weights were obtained for four animals in each group. In separate experiments, pups received intraperitoneal injections of 20, 50, or 100 g goat antihuman IGF-I IgG, goat anti-human IGF-II IgG, or isotype IgG (R&D Systems) in PBS or PBS alone (5 l/g) on days 3, 4, and 5 for death on day 6. The timings of injections for sIGF-R1, anti-IGF-I, and anti-IGF-II were based on our previous experience with other truncated soluble receptors (6, 33, 52) and antibodies (6, 33, 34, 52) to growth factors. For assessment of cell DNA synthesis, pups received 20 g/g ip bromodeoxyuridine (BrdU) 2 h before death.
Tissue preparation. For protein analyses, the lungs of each individual pup were weighed, and the lungs of four animals in each group were pooled and flash-frozen in liquid nitrogen. Lungs were perfusion-fixed over 12 h using 4% (wt/vol) paraformaldehyde in PBS or, for immunodetection of BrdU, 10% (wt/vol) neutral buffered formalin, while inflated with air under a constant airway pressure of 20 cmH 2O. Processing of lung tissue for immunohistochemistry and morphometry was as previously described (6, 15, 23, 27, 33, 34, 52) . Lung sections were stained with hematoxylin and eosin (Surgipath, Winnipeg, MB, Canada) or with Weigert's resorcin-fuchsin stain (Rowley Biochemical Institute, Danvers, MA) and then counterstained with tartrazine (Sigma-Aldrich, St. Louis, MO).
Immunohistochemistry. Immunostaining was performed on lung sections of 5 m thickness using an avidin-biotin-peroxidase complex method (19) . Primary antibody (R&D Systems) dilutions used were 1:25 for goat anti-human IGF-I, 1:80 for goat anti-human IGF-II, and 1:7 for goat anti-human IGF-R1. The specificities of these antibodies were confirmed by immunoadsorption of the antibody with an eightor fivefold excess by weight of either recombinant human IGF-I/II (rhIGF-I/II) or rhIGF-R1 (R&D Systems), respectively. Antibodies to IGF-I from numerous suppliers were tested for specificity by immunoadsorption, but only the one identified above (AF-291-NA; R&D Systems) gave specific staining. It was therefore also used for Western blots and for injections in vivo. Secondary antibodies were biotinconjugated donkey anti-goat IgG (Santa Cruz Biotechnology, Santa Cruz, CA) used at a dilution of 1:200. For assessment of inflammatory cell influx, a 1:200 dilution of a mouse anti-rat antibody to CD-68 (Serotec, Oxford, UK) was used to identify macrophages, and a 1:300 dilution of a rabbit polyclonal antibody to the synthetic peptide Ly-6G (Biorbyt, Cambridge, UK) was used to identify neutrophils (46) . Secondary antibodies were biotin-conjugated goat anti-mouse or antirabbit IgGs (Santa Cruz Biotechnology) used at a dilution of 1:200. A BrdU In Situ Detection Kit (BD Biosciences Pharmingen, San Diego, CA) was used for immunohistochemical staining of BrdU to identify cells undergoing DNA synthesis. A peroxidase immunohistochemistry detection kit was used to identify apoptosis-specific DNA fragmentation by TdT-dUTP nick end labeling (Millipore, Billerica, MA), as previously described (23) .
Hart's elastin staining. Tissue sections were stained using Weigert's resorcin-fuchsin and counterstained with tartrazine, as previously described (26, 27) . Background staining was digitally subtracted before threshold analysis of stained images, which was used to quantify elastin fiber density (14) . The percent area occupied by elastin fibers was calculated by dividing the pixel fractional area for elastin by the pixel fractional area for all tissue (3). These same slides were used for estimations of small vessel density because of the close relationship between vessel formation and alveologenesis (47) . Only vessels with both inner and outer elastin bands, to identify arterioles, and arbitrarily selected outside diameters of 20 -65 m as assessed by superimposed concentric rings, were counted.
Western analyses. Western blot analyses of lung tissue lysates were conducted as previously described (6, 26, 27, 33, 36) . Supernatants of lung tissue lysates, representing the cytoplasmic fractions, were stored at Ϫ80°C. Protein content of extracts was determined using a protein assay kit (Bio-Rad Laboratories, Hercules, CA). Membranes were incubated overnight at 4°C with 1:1,250 dilutions of goat polyclonal antibodies to human IGF-I, human IGF-II, or human IGF-R1 (R&D Systems) as well as a 1:100,000 dilution of mouse monoclonal antibody to ␤-actin (Sigma-Aldrich), as an internal control. Other membranes were incubated overnight at 4°C with 1:500 dilutions of rabbit polyclonal antibodies to FGF-2 and -R1, IGF-R1␤, PDGF-AA, -BB, -R␣, and R␤, and VEGF-A and -R2 (Santa Cruz Biotechnology), a 1:2,000 dilution of a rabbit monoclonal antibody to the phosphorylated ␤-chain of the IGF-R1 (Cell Signaling Technology, Beverly, MA), and a 1:5,000 dilution of a rabbit polyclonal antibody to type I collagen (Abcam, Cambridge, MA) or, as an internal control, to a 1:10,000 dilution of mouse monoclonal antibody to ␤-actin (SigmaAldrich). After being washed, the membranes were incubated with secondary horseradish peroxidase-conjugated donkey anti-goat IgG (Santa Cruz Biotechnology) or a horseradish peroxidase-conjugated goat anti-rabbit IgG (Cell Signaling Technology) at dilutions of 1:2,000 for 2 h or a goat anti-mouse IgG (Millipore) at a dilution of 1:200,000 (IGF-I, IGF-II, and IGF-R1 blots) or 1:20,000 (procollagen I blot) for 1 h. Integrated band densities were calculated after subtraction of background values, as previously described (52) . When background coloration was inhomogeneous, background values were subtracted for individual lanes.
Immunoprecipitation. For immunoprecipitation of the ␤-chain of the IGF-R1, a rabbit polyclonal antibody (Santa Cruz Biotechnology) was added to lysates (2 g antibody/500 g protein) and incubated at 4°C overnight. Packed protein A/G agarose (40 l beads/500 g protein; Santa Cruz Biotechnology) was then added and incubated at room temperature for 4 h with agitation.
Analyses of alveolar formation. Blinded analyses were all performed using 4 tissue sections per animal and 10 random nonoverlapping images per section. A section average was calculated from the average of the 10 images. The average values of the four sections were used to calculate individual animal averages. All measurements were performed on 5-m sections. Calculations of tissue fraction, mean linear intercept, alveolar density, and secondary crest volume density were as previously described (23, 26, 27, 33, 34) . A 130-point counting grid was used to calculate the tissue fraction, as the fraction of total points overlying tissue. Postfixation lung volumes were determined by water displacement.
In vitro studies. Fibroblasts were purified from day-6 lungs by trypsinization and differential adherence, as previously described (42, 48) , and maintained in culture in 21% O2-5% CO2-74% N2 with phenol red-free Dulbecco's modified Eagle's medium (Life Technologies, Burlington, ON, Canada) and 20% (vol/vol) fetal bovine serum (Life Technologies). Cells were passaged one time and split 1:3. Cells were exposed to 30 ng/ml rhIGF-I (R&D Systems) for 48 h under serum-free conditions, when subconfluent, for study of DNA synthesis, or 48 and 66 h for qPCR. DNA synthesis was assessed by the incorporation of [ 3 H]thymidine (MP Biomedicals, Santa Ana, CA) into DNA as previously described (42, 48) . Estimations of cell tropoelastin and type I collagen mRNA content were by qPCR. Cellular RNA was extracted (Absolutely RNA Miniprep Kit; Agilent/Stratagene, La Jolla, CA) and reverse transcribed (AffinityScript; Agilent). qPCR was performed on a Stratagene MX3000P qPCR system using SYBR Green qPCR Master Mix (SA Biosciences, Frederick, MD). Cycling conditions were 95°C for 10 min followed by 40 cycles of 95°C for 15 s and 60°C for 60 s. Primer sequences (5=-3=) were as follows: tropoelastin (RefSeq NM_012722) forward GTGATCCCTGGTGCTGTAGG, reverse GAGAAAGTC-CAAACCCAGGTC; collagen type I (RefSeq NM_053304) forward GCCTCCCAGAACATCACCTA, reverse GACTGTCTTGCCCC-AAGTTC. A standard curve for each primer set was run, using a rat lung cDNA standard (Agilent), to ensure that reaction efficiency was equiva-lent to primers for the housekeeping gene ␤-actin. Following each standard curve reaction, molecular weight standards (O'GeneRuler; Fermentas, Burlington, ON, Canada) and PCR products underwent DNA gel electrophoresis to confirm the presence of a single product of predicted length. A dissociation (melt) curve was run for each set of samples to exclude nonspecific product formation. Samples were run in duplicate, and fold or fraction change in expression relative to control samples was calculated by the 2
Ϫ⌬⌬Ct method using Stratagene MxPro software (version 4.01).
Data presentation. All values are presented as means Ϯ SD. Protein measurements for individual groups were obtained from four separate litters. For lung structure analyses, each individual group was made up of four average-sized pups, each from different litters. For cell culture experiments, each group represented analyses from four separate wells. For multiple groups, one-way ANOVA was used to determine statistical significance (P Ͻ 0.05), followed by post hoc analyses using Tukey's test when significant differences were found between groups. For two groups, a t-test was used to determine statistical significance (P Ͻ 0.05). These, and linear regression analyses, were performed using the SigmaStat (SPSS, Chicago, IL) analysis program.
RESULTS
As shown in Fig. 1 , A, B, and C, the distributions of IGF-I, IGF-II, and IGF-R1 in the saccular/alveolar regions of neonatal rat lungs at days 4, 7, 10, and 14 of life were widespread and diffuse, and the lung contents of IGF-I, IGF-II, and IGF-R1 did not appear to vary greatly at any of the time points studied. These qualitative assessments were confirmed by Western analyses of the lung contents of IGF-I and -II ( Fig. 2 ) and IGF-R1 (Fig. 3 ). There was a suggestion of slightly reduced immunostaining for IGF-I at day 10, and there was a small parallel reduction in the quantitative analysis at the same time point, but this was not statistically significant. There was also a suggestion of slight reductions for IGF-II at days 7 and 10, with small parallel reductions in the quantitative analyses at the same time points, but these were not statistically significant. Similarly, there was also a suggestion of slight reductions for IGF-R1 at days 7 and 14, with small parallel reductions in the quantitative analyses at the same time points, but these were again not statistically significant.
Initial dosimetry was performed using increasing doses of the intervention, sIGF-R1. Pups treated on day 2 and killed on day 4 had dose-dependent reductions, as assessed by linear regression analyses in BrdU-positive cells per unit area ( 
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At the highest dose of sIGF-R1 tested, 20 g/g body wt, the effects on all of the above parameters were statistically significant by one-way ANOVA. There was no significant effect of sIGF-R1 on body weight on day 4 (data not shown).
Following these preliminary analyses, pups received sIGF-R1 at 20 g/g body wt on day 2 and day 5 for death on days 6 or 7. That sIGF-R1 at 20 g/g body wt was modifying signaling through the IGF-R1 was confirmed by demonstrating significantly reduced phosphorylation of immunoprecipitated IGF-R1␤ following treatment with sIGF-R1 (Fig. 5) . IGF-R1␤ was used for this analysis because it is the ␤-chain of IGF-R1 that is phosphorylated during activation of the receptor (17) . Pups that received sIGF-R1 had significantly reduced lung weights and lung weight-to-body weight ratios compared with untreated or vehicle-treated pups, but there were no significant effects on body weights or postfixation lung volumes and lung volume-to-body weight ratios, nor did treatment with sIGF-R1 result in neutrophil or macrophage influxes or any change in apoptotic cell density (Table 1) . Relative to vehicle-treated pups (Fig. 6A) , the lung tissue of sIGF-R1-treated pups (Fig. 6B ) appeared to have enlarged air spaces with an overall reduction in tissue/field of view. Significantly enlarged distal air spaces were confirmed by measurement of mean linear intercept (Fig. 6C) , and a significantly reduced tissue mass was confirmed by measurement of the tissue fraction (Fig. 6D) . Treatment with sIGF-R1 also caused a significant reduction in secondary crests per unit area (Fig. 6E ), but this reduction was no longer present after correction for lung tissue mass (Fig. 6F) . A reduction in small vessel density per unit area was also evident (Fig. 6G) , but, again, no reduction was evident after correction for lung tissue mass (Fig. 6H) .
Pups that had received 20 g/g body wt sIGF-R1 on day 2 and day 5 had a significant reduction in lung cell DNA synthesis on day 7, as assessed by BrdU-positive cells per unit area (Fig. 7A ), but no significant difference between groups was evident after correction for lung tissue mass (Fig. 7B ). Similar findings were evident when DNA synthesis in secondary crests alone was assessed, with a significant reduction per unit area (Fig. 7C ), but no significant change after correction for lung tissue mass (Fig. 7D ), or when expressed as a proportion of total secondary crests (Fig. 7E) . The overall reduction in BrdU-positive cells per unit area, after treatment with sIGF-R1, was associated with a significant reduction in alveolar density per unit area compared with both control groups (Fig. 7F ). Lung homogenates from day-6 pups that had received 20 g/g body wt sIGF-R1 on day 2 and day 5 also had an apparent reduction in type I procollagen content (Fig. 8A ) on Western analysis, which was confirmed as a significant reduction by densitometry (Fig. 8B ) of the most prominent band at 120 kDa, a molecular weight previously reported for a rat procollagen polypeptide (13) . Western analyses of these same lung homogenates revealed no sIGF-R1-induced reductions in the contents of the other growth factors or growth factor receptors tested: FGF-2 and -R1, PDGF-AA, -BB, -R␣ and -R␤, or VEGF-A and VEGF-R2 (data not shown). Elastin staining of lung tissues from day-7 pups that had received no treatment (Fig. 8C ) or vehicle treatment (Fig. 8D ) appeared to have a greater elastin content than those from pups that had received sIGF-R1 (Fig. 8E ). Densitometric analysis of elastin fiber density confirmed a significant sIGF-R1-induced reduction (Fig. 8F) . We recognized that the findings of reduced procollagen and elastin content in lung tissues following treatment with sIGF-R1 would probably represent reduced synthesis but could not exclude enhanced degradation. We therefore isolated fibroblasts from day-6 lungs for cell culture and looked at the effects of exposure to 30 ng/ml IGF-I, as defined by preliminary experiments, on DNA synthesis and on type I collagen and elastin mRNA synthesis by qPCR. After a 48-h exposure to IGF-I, there was a significant increase in DNA synthesis, as assessed by [ 3 H]thymidine incorporation into DNA (Fig. 9A) . After a 48-h exposure to IGF-I, there was no significant effect on type I collagen or tropoelastin mRNA content (data not shown). Based on observations by others (40), we extended the All data are presented as means Ϯ SD; n ϭ 4 average-sized pups/group, each from different litters. Treatment with soluble (s) IGF-I receptor (IGF-R) 1 resulted in significant reductions in lung weight (LW) and lung/body weight ratio (LW/BW), but not body weight (BW) at day 6. Treatment with sIGF-R1 had no effect on postfixation lung volumes (LV), LW, LV/BW, neutrophil, macrophage, or apoptotic cell counts at day 7. Lung neutrophil, macrophage, and apoptotic cell counts were determined using 4 tissue sections/animal and 10 random nonoverlapping images/section. *P Ͻ 0.05 vs. both other groups by 1-way ANOVA.
exposure time to 66 h, whereupon we did observe significant increases in type I collagen (Fig. 9B ) and elastin mRNA (Fig.  9C ) content. These in vitro observations suggest that the in vivo observations of reduced lung contents of procollagen I and elastin were the result of inhibition of IGF-R1-mediated synthesis by sIGF-R1.
Relative to vehicle-treated pups (Fig. 10A) , the lung tissue of pups that had received 100 g of anti-IGF-I on days 3, 4, and 5 before death on day 6 appeared to have enlarged air spaces with an overall reduction in tissue/field of view (Fig. 10B ). Rat pups that had received 100 g of anti-IGF-I had a significant increase in mean linear intercept (Fig. 10C ) and a significant decrease in tissue fraction (Fig. 10D ). Rat pups that had received 50 or 100 g of anti-IGF-I had significant reductions in secondary crests per unit area (Fig. 10E ), but significance was lost after normalization to tissue fraction (Fig. 10F ). Rat pups that had received 100 g of anti-IGF-I also had significant reductions in small vessel density per unit area (Fig. 10G) , but significance was lost after normalization to tissue fraction (Fig. 10H ). Rat pups that had received 100 g of anti-IGF-I had a significant reduction in BrdU-positive lung cells per unit area (Fig. 11A ), but significance was lost after normalization to tissue content (Fig. 11B) . Anti-IGF-I at 100 g also caused a significant reduction in BrdU-positive secondary crests per unit area (Fig. 11C) , but significance was also lost after normalization to tissue content (Fig. 11D) . None of the interventions affected the ratio of BrdU-positive secondary crests to total secondary crests (Fig. 11E) . Anti-IGF-I at 50 and 100 g caused a significant reduction in alveolar density per unit area (Fig. 11F ). Rat pups that had received 100 g of anti-IGF-I on days 3, 4, and 5 before death on day 6 had no apparent alteration in lung type I procollagen content on Western analysis (Fig. 12A) , which was confirmed by densitometry (Fig. 12B) . Elastin staining of lung tissues from pups that had received no treatment (Fig. 12C ) or vehicle treatment (Fig. 12D ) appeared to have a greater elastin content than those from pups that had received anti-IGF-I (Fig. 12E) . Densitometric analysis of elastin fiber density revealed a significant anti-IGF-I-induced reduction (Fig. 12F) . Anti-IGF-I at 100 g had no effect on lung or body weights, lung-to-body weight ratios, postfixation lung volumes and lung volume-to-body weight ratios, or neutrophil or macrophage influxes (Table 2) .
Anti-IGF-II at 20, 50, or 100 g on days 3, 4, and 5 before death on day 6 had no effect on BrdU uptake by lung cells (Fig. 13) . A role for IGF-II in postnatal lung growth was not further pursued.
DISCUSSION
A strength of this study is the use of specific antibodies to IGF-I, IGF-II, and IGF-R1, as determined by immunoadsorption of the antibody with an excess of rhIGF-I, rhIGF-II, and rhIGF-R1. It was remarkable how many of the commercial antibodies to IGF-I that we assessed lacked specificity, which may account for some of the discrepancies evident in the lung IGF literature (29, 35) . Differences in antibody specificity could also account for our finding of relatively stable IGF-I/IGF-R1 content after birth when others have described postnatal age-dependent variability (24) . We acknowledge that minor variations between time points are possible and may have been detected had we used a larger sample size. For our studies with anti-IGF antibodies, we used isotype IgG as negative controls. In a number of previous studies in which we have targeted growth factor receptors with truncated soluble receptors (6, 33, 34, 52), we have used a truncated soluble receptor to nerve growth factor as a negative control. Because those studies all showed a uniform lack of effect of the truncated soluble receptor to nerve growth factor, we did not feel it neces- sary to repeat the negative control intervention in this study. As a limitation of this study, we acknowledge that the analyses of lung structure used in this study are relatively crude compared with the technologically advanced, elegant, and precise morphometric approaches applied by some investigators (38) . However, the approaches that we use have the advantage of simplicity and have previously been used by us to identify large differences between study groups (6, 23, 27, 33, 34 ).
Previous publications have described results consistent with the IGF-I/IGF-R1 pathway being involved in postnatal lung growth (18, 41) , but this is, to our knowledge, the first study to report targeted interventions against the IGF-R1 and IGF-I with an assessment of postnatal alveologenesis. Our data suggest that the IGF-I/IGF-R1 pathway does regulate both postnatal lung growth, as reflected by lung weights and the number of BrdU-positive lung cells, and growth of secondary crests Relative to vehicle-treated pups (A), the lungs of pups treated with 100 g/day of anti-IGF-I (B) appeared to have enlarged air spaces with an overall reduction in tissue/field of view. Original magnification ϫ200. Bar ϭ 100 m. Anti-IGF-I at 100 g/day caused a significant increase in mean linear intercept (C), and a significant reduction in tissue fraction (D). Anti-IGF-I at 50 and 100 g/day also caused a significant reduction in secondary crests per unit area (E), but significance was lost after normalization to tissue content (F). Similarly, anti-IGF-I at 100 g/day caused a significant reduction in small vessels per unit area (G), but significance was lost after normalization to tissue content (H). *P Ͻ 0.05 by 1-way ANOVA compared with both control groups. Values are means Ϯ SD for 4 average-sized pups from each of 4 different litters.
during the formation of alveoli, as reflected by BrdU-positive secondary crests. Our studies were deliberately targeted to the phase of lung growth occurring between days 3 and 7 of life, since this is in the middle of the threefold increase in alveolar density that occurs between days 3 and 10 of life (30) . The effect of IGF-I, acting through the IGF-R1, on secondary crest formation appears to differ from the effects of other growth factors such as PDGF-BB (6), HGF (33) , and FGF-7 (34) in that its effect is not specific for secondary crest formation. Interventions targeting PDGF-BB (6), HGF (33) , and FGF-7 (34) all resulted in a significant inhibition of secondary crest formation and secondary crest DNA synthesis, which retained significance after correction for tissue mass. This contrasts with findings for the intervention targeting the IGF-I/IGF-R1 pathway in which the inhibition of secondary crest formation and secondary crest DNA synthesis lost significance after correction for tissue mass. This suggests that, although blockade of the IGF-I/IGF-R1 pathway results in impaired secondary crest formation, as reflected in secondary crest density per unit area, and alveolar formation, as reflected in values for mean linear intercept, this is a nonspecific effect of a widespread impairment of lung cell DNA synthesis rather than a specific impairment of secondary crest formation. The effects of interventions targeting IGF-I, acting through the IGF-R1, also differ from the effects seen after targeting PDGF-BB (6), HGF (33) , and FGF-7 (34) in that the latter interventions affected lung structure without affecting lung weight, whereas the effect of the intervention targeting the IGF-R1 resulted in a reduced lung weight. This finding is consistent with the observation that less-than-complete null mutations of IGF-R1 (consistent with survival) result in long-term effects on lung growth (18) . IGF-I could also be influencing alveologenesis through its mitogenic effect on pulmonary small vessel endothelial cells (43) , since angiogenesis is widely believed to be a critical regulator of alveologenesis (47) .
The global effect of the IGF-I/IGFR1 pathway on lung growth may be regulated in a number of ways, most obviously, through its action as an autocrine or paracrine growth factor. There could also be secondary effects through one or a number of its regulatory binding proteins. We made no attempt in this study to assess effects on the binding proteins, since the question being addressed was simply whether the IGF-I/ IGF-R1 pathway regulated postnatal alveologenesis. We did assess whether inhibition of the pathway affected collagen synthesis and elastin fiber density. We had anticipated that these would be affected because of the reported regulation of tropoelastin synthesis (32) and collagen synthesis (11) by IGF-I. Others have reported that neonatal rat lung fibroblasts do not respond to IGF-I by increasing elastin synthesis (37). However, we were able to confirm increased neonatal lung fibroblast tropoelastin and type I collagen mRNAs in response to IGF-I exposure, although only after a 66-h exposure and not after a 48-h exposure. A similar need for a prolonged exposure to IGF-I before any change in neonatal lung fibroblast tropoelastin mRNA is observed has been reported by others (40) . Anti-IGF-I at 100 g/day also caused a significant reduction in BrdU-positive secondary crests per unit area (C), but significance was also lost after normalization to tissue content (D). None of the interventions affected the ratio of BrdU-positive secondary crests to total secondary crests (E). Anti-IGF-I at 50 and 100 g/day caused a significant reduction in alveolar density per unit area (F). *P Ͻ 0.05 by 1-way ANOVA compared with both control groups. Values are means Ϯ SD for 4 average-sized pups from each of 4 different litters.
Both procollagen synthesis, normalized to ␤-actin, and elastin fiber density, normalized to tissue fraction, were decreased by interventions targeting the IGF-R1. These changes may have had a secondary effect on alveologenesis. The composition of the extracellular matrix is recognized to regulate lung development and alveologenesis (21, 28) , and the presence of elastin in the lung is essential for alveologenesis (51) . Targeting the IGF-R1 reduced lung weight and procollagen content, but these effects were not observed when IGF-I alone was targeted. Likely explanations include the presence of other ligands that activate the IGF-R1, such as IGF-II and insulin, which are not affected by the anti-IGF-I antibody. Although we saw no effect of anti-IGF-II on lung cell DNA synthesis, and despite literature suggesting that IGF-II has no effect on postnatal growth in mice (2), we cannot absolutely exclude there being an observable effect had we used greater antibody concentrations. Of the findings with sIGF-R1 and anti-IGF-I interventions, many of the significant effects per unit area observed with our analyses were lost after correction for tissue volume. These findings, in addition to mean linear intercept and tissue fraction, could all be accounted for by inflation artifact. However, we observed no significant differences in postinflation lung volumes after either of the interventions, thus excluding inflation artifact. We can therefore speculate that the IGF pathway is functioning perfectly adequately, with respect to DNA synthesis, but the tissue mass on which it can act is reduced, perhaps as a consequence of an alteration in the composition of the extracellular matrix. Our findings are consistent with those for IGF-I, IGF-II, and IGF-R1 mutation analyses (2) in which the impact of such mutations appeared to be an elongation of cell cycle time. Cell division was not arrested in their absence, but fewer cells were generated. All data are presented as means Ϯ SD; n ϭ 4 average-sized pups/group, each from different litters. Treatment with anti-IGF-I had no significant effects on lung weight, body weight, lung/body weight ratio, postfixation lung volumes, lung/body weight ratio, or neutrophil and macrophage counts. Lung neutrophil and macrophage counts were determined using 4 tissue sections/ animal and 10 random nonoverlapping images/section. Infants developing the chronic neonatal lung injury, bronchopulmonary dysplasia (BPD), have increased IGF-I in their bronchoalveolar lavage (8) , and IGF-I and IGF-R1 are increased in human lung tissue from infants with respiratory distress syndrome and BPD (10) . Whether these increases are beneficial, detrimental, or both simultaneously is unknown. IGF-I and IGF-R1 are increased in the lungs of adult (16, 31) and neonatal (15, 49) rats exposed to hyperoxia, and adult mice exposed to hyperoxia (22) or bleomycin (12) . Increased lung IGF-I and IGF-R1 may be beneficial in adult lung injury through a mitogenic effect on type II pneumocytes (31, 44) facilitating repair of an injured alveolar epithelium. This may not be true for the neonatal lung because type II pneumocytes isolated from day-7 neonatal lungs, in contrast to those isolated from adult lungs, do not respond to IGF-I by increasing DNA synthesis (45) . Adverse effects of increased IGF-I/IGF-R1 have also been reported. Blockade of the IGF-I/IGF-R1 pathway has been shown to be protective against both O 2 -(22) and bleomycin-induced (12) lung injury in adult mice, possibly by limiting neutrophil chemotaxis, increasing fibroblast apoptosis, or by reducing fibroblast proliferation (9), thereby reducing fibrosis. Neonatal mice hypomorphic for the IGF-R1 also have improved survival in hyperoxia with less lung injury (1) . Within the context of this study, we did observe IGF-I to stimulate neonatal fibroblast DNA synthesis but did not see any effect of inhibition of the IGF-I/IGF-R1 on apoptosis in the neonatal lung.
In summary, the IGF/IGF-R1 pathway does regulate alveologenesis, but as a catalyst of lung cell DNA synthesis, rather than as a specific effector of secondary crest formation. The increase in alveolar numbers after birth in the rat is linear over the first 21 days of life (36) . The fact that the relative amounts of IGF-I, IGF-II, and IGF-R1 do not change throughout the first 14 days of life is therefore not surprising and is consistent with a catalytic effect throughout this initial period of alveolarization. This catalytic effect may be mediated through effects of the IGF/IGF-R1 pathway on lung tissue matrix composition.
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